Citadel Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Citadel Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.3K	Sell	15,300 -29,700	-66%	-$108K	﹤0.01%	13026
2026 Q1	$139K	Sell	45,000 -4,800	-10%	-$11.3K	﹤0.01%	11749
2025 Q4	$75.2K	Buy	+49,800	New	+$118K	﹤0.01%	11836
2025 Q2	–	Sell	-10,500	Closed	-$35.6K	–	13152
2025 Q1	$35.6K	Sell	10,500 -6,500	-38%	-$26.7K	﹤0.01%	12647
2024 Q4	$70K	Buy	+17,000	New	+$67K	﹤0.01%	11969
2024 Q2	–	Sell	-500	Closed	-$1.03K	–	14512
2024 Q1	$1.03K	Buy	500 +100	+25%	+$178	﹤0.01%	14198
2023 Q4	$720	Buy	+400	New	+$556	﹤0.01%	13953
2023 Q2	–	Sell	-5,900	Closed	-$13.9K	–	14529
2023 Q1	$13.9K	Buy	+5,900	New	+$15.8K	﹤0.01%	13336
2022 Q3	–	Sell	-20,000	Closed	-$49K	–	12856
2022 Q2	$49K	Buy	+20,000	New	+$61K	﹤0.01%	11950
2021 Q4	–	Sell	-12,900	Closed	-$80K	–	14007
2021 Q3	$80K	Buy	+12,900	New	+$90.2K	﹤0.01%	13070

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Citadel Advisors's ELDN Position: Q2 2026 in Review

Citadel Advisors opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 215,973 shares worth $851K. The stake represents ﹤0.01% of the portfolio and ranks #8610 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ELDN as recently as Q2 2025.

Citadel Advisors first reported a position in ELDN in Q2 2019 and has held it in 13 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Citadel Advisors held 215,973 shares of Eledon Pharmaceuticals worth $851K as of Q2 2026.
Eledon Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8610 holding.
Citadel Advisors first reported a position in Eledon Pharmaceuticals in Q2 2019 and has held it in 13 quarters since.
161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.